drug · oligonucleotide
olezarsen sodium
Marketedupdated 6mo agoby $IONS IONIS PHARMACEUTICALS INC🔗 ChEMBL
Approvedcommunity read0 votes
Oligonucleotide drug with a maximum clinical stage of Unknown (across all indications), with 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 19, 2031
~5.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- May 1, 2034method-of-use (U-4050)US 12509684
- May 1, 2034compositionUS 9127276
- May 1, 2034compositionUS 9163239
- May 1, 2034compositionUS 9181549
- Feb 14, 2034method-of-use (U-4050)US 9593333
- Apr 27, 2032method-of-use (U-4050)US 9157082
FDA exclusivities (1)
- Dec 19, 2031ODE-515Orphan Drug (7y)
News(10)
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 3d ago
- STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drugIonis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug.stat · 7d ago
- GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatmentHibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug ap…biospace · 27d ago
- On the move: 4 rare disease companies hiring nowBiotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.biospace · 1mo ago
- Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodA late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay…biospace · 1mo ago
- Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipelineAfter Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. But a follow-up scan a year later, just d…fiercebiotech · 2mo ago
- FDA approves Ionis’ antisense drug as first targeted therapy for Alexander diseaseZanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neuro…biospace · 2mo ago
- ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsyAt a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.biopharma_dive · 2mo ago
- Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts splitSafety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.biospace · 2mo ago
- BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotechBioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…biospace · 3mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that